Dramatic response to cabozantinib in patients with hyperprogression after anti-PD-1 therapy

被引：0
|
作者：
Schlack, K. [1 ]
Krabbe, L. -M [1 ]
Schrader, A. J. [1 ]
Klaile, Y. [1 ]
Boegemann, M. [1 ]
机构：
[1] Univ Klinikum Munster, Klin Urol & Kinderurol, Munster, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P607
引用
收藏
页码：203 / 204
页数：2
相关论文
共 50 条
  • [31] Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
    Parakh, Sagun
    Park, John J.
    Mendis, Shehara
    Rai, Rajat
    Xu, Wen
    Lo, Serigne
    Drummond, Martin
    Rowe, Catherine
    Wong, Annie
    McArthur, Grant
    Haydon, Andrew
    Andrews, Miles C.
    Cebon, Jonathan
    Guminski, Alex
    Kefford, Richard F.
    Long, Georgina V.
    Menzies, Alexander M.
    Klein, Oliver
    Carlino, Matteo S.
    BRITISH JOURNAL OF CANCER, 2017, 116 (12) : 1558 - 1563
  • [32] Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
    Park, J. J.
    Parakh, S.
    Mendis, S.
    Rai, R.
    Lo, S.
    Haydon, A.
    Andrews, M. C.
    Cebon, J.
    Guminski, A.
    Kefford, R.
    Long, G. V.
    Menzies, A. M.
    Klein, O.
    Carlino, M. S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [33] Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
    Sagun Parakh
    John J Park
    Shehara Mendis
    Rajat Rai
    Wen Xu
    Serigne Lo
    Martin Drummond
    Catherine Rowe
    Annie Wong
    Grant McArthur
    Andrew Haydon
    Miles C Andrews
    Jonathan Cebon
    Alex Guminski
    Richard F Kefford
    Georgina V Long
    Alexander M Menzies
    Oliver Klein
    Matteo S Carlino
    British Journal of Cancer, 2017, 116 : 1558 - 1563
  • [34] Pneumonitis with anti-PD-1/PD-L1 therapy
    Naidoo, J.
    Cunningham, J.
    Woo, K. M.
    Hellmann, M. D.
    Postow, M. A.
    Drilon, A. E.
    Chaft, J. E.
    Lesokhin, A. M.
    Segal, N. H.
    Callahan, M. K.
    Rudin, C. M.
    Iyriboz, T.
    Wolchok, J. D.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S103 - S103
  • [35] Gut Mycobiota Dysbiosis Is Associated with Melanoma and Response to Anti-PD-1 Therapy
    Szostak, Natalia
    Handschuh, Luiza
    Samelak-Czajka, Anna
    Tomela, Katarzyna
    Pietrzak, Bernadeta
    Schmidt, Marcin
    Galus, Lukasz
    Mackiewicz, Jacek
    Mackiewicz, Andrzej
    Kozlowski, Piotr
    Philips, Anna
    CANCER IMMUNOLOGY RESEARCH, 2024, 12 (04) : 427 - 439
  • [36] Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
    Hugo, Willy
    Zaretsky, Jesse M.
    Sun, Lu
    Song, Chunying
    Moreno, Blanca Homet
    Hu-Lieskovan, Siwen
    Berent-Maoz, Beata
    Pang, Jia
    Chmielowski, Bartosz
    Cherry, Grace
    Seja, Elizabeth
    Lomeli, Shirley
    Kong, Xiangju
    Kelley, Mark C.
    Sosman, Jeffrey A.
    Johnson, Douglas B.
    Ribas, Antoni
    Lo, Roger S.
    CELL, 2016, 165 (01) : 35 - 44
  • [37] Complete response of metastatic pleomorphic dermal sarcoma to anti-PD-1 therapy
    Klein, O.
    McTigue, C.
    Wong, Z. W.
    Syme, D. B.
    Hunter-Smith, D. J.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (06) : E189 - E189
  • [38] Role of CXCR3 signaling in response to anti-PD-1 therapy
    Han, Xiao
    Wang, Ying
    Sun, Jing
    Tan, Tao
    Cai, Xiaomin
    Lin, Peinan
    Tan, Yang
    Zheng, Bingfeng
    Wang, Biao
    Wang, Jiawei
    Xu, Lingyan
    Yu, Zhengyi
    Xu, Qiang
    Wu, Xingxin
    Gu, Yanhong
    EBIOMEDICINE, 2019, 48 : 169 - 177
  • [39] Pathological Parameter for Anti-PD-1 Therapy Response Evaluation of Melanoma in Asians
    Jiao, Tao
    Guo, Qian
    Du, Haizhen
    Liu, Xia
    Sun, Hongzhe
    Han, Shuo
    Zhu, Lin
    Zhang, Zhifu
    Li, Na
    Kong, Yan
    LABORATORY INVESTIGATION, 2024, 104 (03) : S531 - S531
  • [40] CLINICAL, RADIOGRAPHIC, AND PATHOLOGIC PREDICTORS OF RESPONSE TO ANTI-PD-1 AND ANTI-PD-L1 THERAPY IN IDH-WILDTYPE GLIOBLASTOMA PATIENTS
    Iorgulescu, Bryan
    Lim-Fat, Mary Jane
    Qin, Lei
    Grant, Gareth
    Huang, Raymond
    Young, Geoffrey
    Reardon, David
    NEURO-ONCOLOGY, 2020, 22 : 8 - 9
12345